Finny logo
Finny logo
Dibs:
Dibs:
0

Akers Biosciences (AKER) stock is dropping like a stone, but for how much longer?

4:48 am ET, 14 Aug 2018

Akers Biosciences (AKER) shares are trading at 0.27.  The company lost more than 70% of its market cap value since late March. What's driving Akers' stock price? What do investors speculate about the price of AKER shares?

Akers is mired with a number of lawsuits.  A shareholder rights law firm Glancy Prongay & Murray started an investigation on behalf of Akers' investors concerning the company and its officers’ possible violations of federal securities laws.  Bronstein, Gewirtz & Grossman also filed a class action lawsuit against Akers Biosciences and its officers, on behalf of shareholders who purchased Akers securities between May 15, 2017, and June 5, 2018.

On the commercial front, however, Akers Biosciences is continuing the push.  The company recently announced an agreement with Appleton Medical Services adding sales and marketing coverage for Akers' heparin-induced thrombocytopenia (HIT) rapid test across an additional 12 states. 

What is the sentiment towards the AKER stock? Our technical analysis shows that: 

  • The stock short-term sentiment (next 30 days) is negative;
  • The mid-term sentiment (3-6 months) is trending negative;
  • The long-term sentiment (9-12 months) is negative. 


Over the last month, Akers Biosciences (AKER) returned -43.3%.

Akers Biosciences Inc (AKER) short share of float is 13.68%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock.

For the latest price and information on Akers Biosciences Inc, please visit Finstead and search for "AKER price" or "AKER news".

Akers Biosciences (AKER): Much Upside?

4:22 pm ET, 16 Apr 2018

Akers Biosciences (NASDAQ: AKER) shares have fallen 2% today. 

Akers is a US-based company focused on developing and supplying rapid health information technologies to healthcare providers and consumers.

In order to enhance sales and marketing of the rapid test for heparin-induced thrombocytopenia (HIT), the company engaged two Independent Sales Representative (ISR) organizations.

It made agreements with Opto-Systems and Herzog Surgical to create awareness about platelet factor 4 among the orthopedic and cardiac surgeons for expanding its point-of-care Heparin/PF4 Rapid Assay product platform.

These commercialization strategies will help Akers become more profitable.

Currently, the stock has a $49 Million market cap. The current price is -74% below its 52-week high, but 4.5x its 52-week low. 

Will Akers bounce back? Per Finstead Research, the company’s stock has the average price target of $4, which is much above its current price ($0.56).

The company forward P/E ratio is valued at 2x, which is fairly low.

A high Short share of float compared to the industry and sector averages indicates potential high volatility in the upcoming days.


Akers Biosciences (AKER): Where Is The Stock Going?

1:39 am ET, 26 Mar 2018

Akers Biosciences (NASDAQ: AKER) stock price has been hovering around $0.80 last week.  Over the last 3 months, Aker’s stock price appreciated around 6x. 

The company focuses on rapid diagnostic science. Its products include clinical and safety diagnostics, wellness products, and tests in development.

Akers’ key product is a rapid antibody test for allergy to a widely-used blood thinner, heparin. Heparin is a frequently used agent because of its low price. Akers’ test is significantly faster than other available alternatives on the market.

The majority of Aker’s revenues is still derived from the heparin test. 

The Company also has a line of breathalyzers for the health and wellness industry that sync with Bluetooth-enabled reading devices. 

The best-known breathalyzer test checks for oxidative stress which is a good indicator of a person’s overall health and well-being. 

The market is optimistic about the breathalyzer test because it could result in significant revenue opportunities for the Company.

Recently, the stock garnered some negative sentiment, because of the reduction of positive inflows by ETFs holding this stock.

According to Finstead Research, the average price target is $4 which is much higher than the current price (hovering around $0.80).

On the basis of forward P/E ratio, AKER is a cheap stock. 

The high Short Share of Float compared to the market, in general, is an indication of potential high volatility that may occur in the upcoming period.


Akers Biosciences Inc (AKER) Stock Guide

Updated at: 1:34 am ET, 12 Oct 2020

Before we start: if you're looking for AKER stock price, you can quickly find it out by visiting Finny and typing "AKER quote". If you're looking for a quick scoop on AKER stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "AKER". You'll get all this info in one place. Or you can just type "AKER news" to get the latest stock news.

Looking to buy or sell Akers Biosciences Inc (AKER)? Interested in getting the full scoop on AKER, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this AKER stock guide, we'll address key questions about AKER, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are AKER earnings?
2. When is AKER earnings date?
3. AKER buy or sell? What is AKER Finny Score?
4. What are the reasons to buy AKER? Why should I buy AKER stock?
5. What are the reasons to sell AKER? Why should I sell AKER stock?
6. What are AKER key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are AKER earnings?

AKER trailing 12-month earnings per share (EPS) is -$4.22.

2. When is AKER earnings date?

AKER earnings date is November 12, 2020.

Analysis

3. AKER buy or sell? What is AKER Finny Score?

#{finnyScore:60}Our quantitative analysis shows 3 reasons to buy and 2 reasons to sell AKER, resulting in Finny Score of 60.

4. What are the reasons to buy AKER? Why should I buy AKER stock?

Here are the reasons to buy AKER stock:

5. What are the reasons to sell AKER? Why should I sell AKER stock?

Let's look at the reasons to sell AKER stock (i.e., the bear case):

Key Stats

6. What are AKER key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for AKER:

Metrics AKER
Price $2.23
Average Price Target / Upside N/A
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Medical Instruments & Supplies
Sector Healthcare
Number of Employees 32
Market Cap $20.5M
Forward P/E Ratio 16.79
Price/Book Ratio 23.78
Revenue (TTM) $862.03K
YoY Quarterly Revenue Growth N/A
Profit Margin 0.00%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us